Trial Profile
A Randomized Phase II Study of Peripheral Androgen Blockade With Bicalutamide Followed by Placebo or Treatment With the Gamma Secretase Inhibitor RO4929097 in Men With Rising PSA After Definitive Local Therapy for Adenocarcinoma of the Prostate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; RG 4733 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 04 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Feb 2012 Interim results for the first 16 enrolled patients presented at the 2012 Genitourinary Cancers Symposium.
- 29 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.